239 related articles for article (PubMed ID: 25411257)
1. Plasma-soluble urokinase-type plasminogen activator receptor levels are associated with clinical and pathological activities in lupus nephritis: a large cohort study from China.
Qin DD; Song D; Huang J; Yu F; Zhao MH
Lupus; 2015 May; 24(6):546-57. PubMed ID: 25411257
[TBL] [Abstract][Full Text] [Related]
2. [Dynamic changes in plasma levels of urokinase type plasminogen activator and urokinase type plasminogen activator receptor in patients with systemic inflammatory response syndrome].
Wu XL; Yu L; Long D; Yang JH; Zhang YC; Geng F
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2011 Aug; 23(8):478-81. PubMed ID: 21878172
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
Zhou H; Wu X; Lu X; Chen G; Ye X; Huang J
Thromb Res; 2009; 123(3):537-42. PubMed ID: 18691743
[TBL] [Abstract][Full Text] [Related]
4. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
Enocsson H; Wetterö J; Skogh T; Sjöwall C
Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
[TBL] [Abstract][Full Text] [Related]
5. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
[TBL] [Abstract][Full Text] [Related]
6. Urine soluble urokinase plasminogen activator receptor as a potential biomarker of lupus nephritis activity.
Burcsár S; Toldi G; Kovács L; Szalay B; Vásárhelyi B; Balog A
Biomarkers; 2021 Jul; 26(5):443-449. PubMed ID: 33825610
[TBL] [Abstract][Full Text] [Related]
7. [Urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor in the seminal plasma and sperm of fertile and oligoasthenozoospermia males].
Wang L; Guan HT; Tian YH; Xiong CL
Zhonghua Nan Ke Xue; 2006 Sep; 12(9):791-3. PubMed ID: 17009528
[TBL] [Abstract][Full Text] [Related]
8. [Expression of urokinase-type plasminogen activator and its receptor in plasma of patients with cerebral infarction].
Song SJ; Hu JB; Wang HX; Wen SQ; Ding MP; Huang JZ
Zhonghua Yi Xue Za Zhi; 2003 Sep; 83(18):1583-5. PubMed ID: 14642114
[TBL] [Abstract][Full Text] [Related]
9. [The plasma levels of urokinase plasminogen activator and urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in patients with different stages of liver cirrhosis following chronic hepatitis B].
Wu XR; Wang Q; Shi SS; Lu MH; Guo WD
Zhonghua Gan Zang Bing Za Zhi; 2004 Feb; 12(2):82-4. PubMed ID: 14980106
[TBL] [Abstract][Full Text] [Related]
10. [Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients].
Zhou Q; Liang LJ; Peng BG; Zhen YY
Ai Zheng; 2006 Nov; 25(11):1433-8. PubMed ID: 17094916
[TBL] [Abstract][Full Text] [Related]
11. Plasma ADAMTS-13 activity in proliferative lupus nephritis: a large cohort study from China.
Tan Y; Luan ZQ; Hao JB; Song D; Yu F; Zhao MH
Lupus; 2018 Mar; 27(3):389-398. PubMed ID: 28786769
[TBL] [Abstract][Full Text] [Related]
12. Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease.
Yeh YH; Wang PH; Lin LY; Tee YT; Chou MC; Yang SF; Tsai HT
Clin Chim Acta; 2013 Jan; 415():138-44. PubMed ID: 23117033
[TBL] [Abstract][Full Text] [Related]
13. Expression of urokinase plasminogen activator and its receptor during acute renal allograft rejection.
Roelofs JJ; Rowshani AT; van den Berg JG; Claessen N; Aten J; ten Berge IJ; Weening JJ; Florquin S
Kidney Int; 2003 Nov; 64(5):1845-53. PubMed ID: 14531820
[TBL] [Abstract][Full Text] [Related]
14. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
Shariat SF; Roehrborn CG; McConnell JD; Park S; Alam N; Wheeler TM; Slawin KM
J Clin Oncol; 2007 Feb; 25(4):349-55. PubMed ID: 17264329
[TBL] [Abstract][Full Text] [Related]
15. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
[TBL] [Abstract][Full Text] [Related]
16. Complexes between urokinase-type plasminogen activator and its receptor in blood as determined by enzyme-linked immunosorbent assay.
De Witte H; Sweep F; Brünner N; Heuvel J; Beex L; Grebenschikov N; Benraad T
Int J Cancer; 1998 Jul; 77(2):236-42. PubMed ID: 9650559
[TBL] [Abstract][Full Text] [Related]
17. Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma.
Casella R; Shariat SF; Monoski MA; Lerner SP
Cancer; 2002 Dec; 95(12):2494-9. PubMed ID: 12467062
[TBL] [Abstract][Full Text] [Related]
18. IFN-γ, CXCL16, uPAR: potential biomarkers for systemic lupus erythematosus.
Wen S; He F; Zhu X; Yuan S; Liu H; Sun L
Clin Exp Rheumatol; 2018; 36(1):36-43. PubMed ID: 28628472
[TBL] [Abstract][Full Text] [Related]
19. Urokinase plasminogen activator (uPA) and its receptor (uPAR) in gestational tissues; Measurements and clinical implications.
Uszyński M; Perlik M; Uszyński W; Zekanowska E
Eur J Obstet Gynecol Reprod Biol; 2004 May; 114(1):54-8. PubMed ID: 15099871
[TBL] [Abstract][Full Text] [Related]
20. The serum levels of connective tissue growth factor in patients with systemic lupus erythematosus and lupus nephritis.
Wang FM; Yu F; Tan Y; Liu G; Zhao MH
Lupus; 2014 Jun; 23(7):655-64. PubMed ID: 24536044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]